Comparative Pharmacology
Head-to-head clinical analysis: INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
The mechanism of action of INPERSOL-LC/LM W/ DEXTROSE 2.5% is based on peritoneal dialysis. Dextrose creates an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (e.g., urea, creatinine) and excess fluid from the blood into the dialysate. Lactate or low magnesium buffer corrects metabolic acidosis by providing bicarbonate precursors.
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, typically 4-5 exchanges per day, as part of continuous ambulatory peritoneal dialysis (CAPD). For automated peritoneal dialysis (APD): 2 liters per cycle, 4-6 cycles per night, with a daytime dwell as prescribed.
None Documented
None Documented
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Intraperitoneal dextrose has a terminal elimination half-life of approximately 1-2 hours, reflecting rapid absorption from the peritoneal cavity followed by systemic metabolism and distribution.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Primarily renal elimination through peritoneal dialysis; approximately 60-80% of dextrose absorbed is metabolized to CO2 and water, with the remainder eliminated via the kidneys. Non-dextrose components are removed via peritoneal dialysis outflow.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution